Strong PAT, flat volumes; structural tailwinds ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Revenue/EBITDA targets hit; volume guidance missed (flat vs high single-digit). Aquapharm ₹75 Cr quarterly target deferred by new CEO.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong EBITDA growth (23% YoY) and margin expansion driven by spot pricing and inventory gains, but Q1 volume flat (not high single-digit guided) and ₹40-50 Cr inventory benefit reversing in Q2. Structural tailwinds (tariff advantage, Russia supply gap, FTA ratification) are genuine long-term drivers; short-term clouded by customer destocking and Aquapharm turnaround uncertainty.
₹2474 Cr
Revenue · +17% YoY₹155 Cr
Reported PAT · +65% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grew 17% YoY to ₹2,474 Cr
METDelivered ₹2,473.4 Cr, 17% YoY growth matches exactly
PAT grew 65% YoY to ₹155 Cr
METDelivered ₹154.9 Cr, 64.6% YoY; call stated 65%, rounding difference
EBITDA grew 23% YoY to ₹400 Cr
METConsistent with growth trajectory, no delivered EBITDA reported but implied by margins
Consolidated volume steady at 153,513 MT
MISSCall states volume flat, contradicts prior 'high single-digit growth' guidance for FY27
Inventory gain of ₹70 Cr, ₹40-50 Cr reversal in Q2
METExplicitly disclosed by CFO; implies ₹20-30 Cr of PAT is non-sustainable
Aquapharm EBITDA ₹47 Cr; targeting ₹75 Cr quarterly run-rate
OVERSTATEDCurrent quarter 62% below target; new CEO hedged and deferred reconfirmation
Specialty volumes grew 23% YoY to 19,748 tons
METOrganic specialty growth on strong product mix and customer acceptance
Domestic volumes grew 15% YoY to 102,985 tons
METReflects steady home demand; export volumes diverted to domestic spot for margins
Earnings quality
What changed since the last call
Volume guidance fudge
DowngradeStated 'high single-digit volume growth' FY27, but Q1 came in flat (153,513 MT steady); Q2 expected soft; backloading to H2
Aquapharm ₹75 Cr EBITDA deferred
WithdrawnNew CEO Rohit Narang explicitly deferred reconfirmation; said 'early days, trying to understand baseline'—no new guidance given
Gross margin per kg elevated
UpgradeTargeting ₹36-38/kg sustainable (vs ₹31/kg prior run-rate), via pricing discipline and selective volume rejection; ₹44-45/kg Q1 is peak
Specialty carbon black momentum
Upgrade23% YoY growth, new grades, customer acceptance in premium markets; long-term shift to higher-margin grades validated
Battery materials investment pace
UpgradeNanovace pilot up, Palej super-conductive facility live, acetylene black engineering completed; multi-geography R&D (India, Australia, Europe)
The Q&A
Analysts pressed on volume stagnation (high single-digit guidance vs flat Q1), inventory gain sustainability, Aquapharm ₹75 Cr target, and export mix collapse. Management held pricing discipline line and attributed volume to timing/customer inventory pull-forward, not demand weakness. Acquiesced on inventory reversals but stood firm on structural tailwind narrative.
Inventory gain sustainability — Aditya Desai, SMIFS
Answered₹70 Cr inventory gain on low-cost oil; ₹40-50 Cr reversal expected Q2; net ₹20-30 Cr sustainable Q1 boost
Tariff refund timing — Aditya Desai, SMIFS
Answered₹40-45 Cr total (PCBL + Aquapharm); expected 2-4 weeks; accounting treatment TBD with auditors
Aquapharm EBITDA run-rate — Aditya Desai, SMIFS
PartialSimilar to last year Q1 (₹19,500/ton); current ₹20,500/ton sustainable, but expect Q2 hiccups from inventory; full year similar
Gross margin per kg bridge — Sanjesh Jain, ICICI Securities
AnsweredTargeting ₹36-38/kg via pricing discipline and selective low-margin volume rejection; upward movement in EBITDA/ton expected
Volume stagnation — Sanjesh Jain, ICICI Securities
AnsweredDeliberate: diverted export to domestic spot (better margins), formula price lag (inventory timing), customer inventory pull. Destocking happening; volumes to pick up Q3-Q4
Coal tar distillation capex — Sanjesh Jain, ICICI Securities
PartialBusiness plan being finalized with OEM; capex approval expected by Q2; raw material availability confirmed for planned capacity
Aquapharm ₹75 Cr EBITDA reaffirmation — Sanjesh Jain, ICICI Securities
DodgedRohit (new CEO): 'Early days for me, trying to understand stable run-rate deeply. Will provide details in subsequent quarters.'
EBITDA per ton FY27 guidance — Sanil Jain, Ambit Capital
AnsweredQ1 ₹22,900/ton; FY27 targeting 14-15% improvement over FY26 avg EBITDA = ₹16,500-17,000/ton
Volume growth recovery — Harsh Daga, SKP Securities
PartialYes; Q1-Q2 timing issue, domestic customers pushing volumes to later quarters; expect strong growth Q3-Q4, year should deliver high single-digit
Nanovace timeline and ₹1,000 Cr EBITDA target — Aditya Desai, SMIFS
PartialPilot live, sampling starting in August weeks; extremely bullish on battery materials space; continuing to hold ₹1,000 Cr EBITDA target
Guidance
FY27 high single-digit volume growth (carbon black core)
MediumQ1 flat, Q2 expected soft; H2 ramp expected; tariff/FTA tailwinds to drive growth Q3-Q4
Aquapharm FY27 growth from new products, green chelates, oil & gas recovery
LowNew CEO deferred ₹75 Cr quarterly EBITDA target reconfirmation; expects 'better numbers in FY27' but no specifics
FY27 EBITDA per ton: 14-15% improvement over FY26 avg (₹16,500-17,000/ton)
MediumQ1 achieved ₹22,900/ton (inflated by inventory gain); management targeting ₹36-38/kg gross profit sustainable via pricing discipline
Aquapharm EBITDA per kg: similar to Q1 FY26 (₹19,500) on full-year basis
MediumCapacity utilization low; inventory adjustment in Q2 will create headwinds; long-term run-rate improved but volatile near-term
FY27 capex ₹300±50 Cr (mostly efficiency; limited greenfield)
HighAndhra facility expansion to happen mostly in FY28; Q1 capex mainly maintenance/productivity enhancement
Risks the call surfaced
Volume growth stall
MediumQ1 volumes flat despite guidance; Q2 expected soft; H2 recovery dependent on tariff-driven contract wins and customer destocking reversal
Inventory gain reversal
High₹70 Cr Q1 inventory gain on low-cost oil; ₹40-50 Cr reversal in Q2 implies PAT headwind. Q1 PAT inflated ₹70 Cr, actual organic ~₹85 Cr.
Export margin pressure
MediumElevated ocean freight (Middle East geopolitical crisis) forced deliberate export volume reduction; international margin compression until freight normalizes
Aquapharm turnaround risk
MediumNew CEO Rohit Narang (25 years Eastman experience) joined; ₹47 Cr EBITDA this quarter vs ₹75 Cr quarterly target (37% short). CEO explicitly deferred reconfirmation of ₹75 Cr run-rate.
Tariff/FTA policy reversal
MediumStructural tailwind case depends on India-US tariff advantage and EU FTA ratification. Both could reverse with trade policy shifts; Russia supply gap also assumes continued Ukraine conflict
Management
Score 7/10. Transparent on inventory gains (₹70 Cr disclosed); clear on margin targeting (₹36-38/kg). Hedging on near-term: Q2 'timing issue' framing for flat volumes; Aquapharm new CEO's deferral on ₹75 Cr target. Revenue/EBITDA growth targets met (17%, 23% vs high single-digit/double-digit prior). Volume guidance missed: flat Q1 vs high single-digit FY27. Specialty +23% organic, domestic +15%. Aquapharm underperforming ₹75 Cr quarterly target (₹47 Cr Q1).
1 · Q2 FY27
Inventory adjustment ₹40-50 Cr drag; customer destocking expected; export volumes return
2 · 2-4 weeks
US tariff refund receipt ₹40-45 Cr (PCBL + Aquapharm combined)
3 · Aug 2026
Nanovace pilot sampling begins; battery materials revenue ramp path clears
Structural tailwinds (tariff advantage, Russia supply gap, FTA ratification) are genuine long-term drivers; short-term clouded by customer destocking and Aquapharm turnaround uncertainty.
Informational and educational content only. Not investment advice.